This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

(Currently Amended): A method of treatment for a mammal suffering from a
dermatologic condition <u>selected from contact dermatitis</u>, <u>skin irritation</u>, <u>acne</u>, <u>rosacea</u>, <u>and</u>
<u>psoriasis</u>, comprising administering a therapeutically effective amount of a compound of
Formula I.

wherein:

- R¹ is: C(O)OR; -C(O)NR'R"; -CH₂OR"; cyano; optionally substituted heterocyclyl; optionally substituted heterocyclyl-alkyl; optionally substituted heteroaryl, or optionally substituted heteroaralkyl;
- R² is: optionally substituted alkyl; optionally substituted cycloalkyl; optionally substituted aryl; optionally substituted aralkyl; optionally substituted heterocyclyl; optionally substituted heteroaralkyl; an optionally substituted nucleoside; an optionally substituted amino acid; or an optionally substituted di-tri- or tetra-peptide;
- R³is: optionally substituted alkyl; optionally substituted cycloalkyl; optionally substituted aryl; optionally substituted aralkyl; optionally substituted heterocyclyl; optionally substituted heteroaralkyl; an optionally substituted nucleoside; an optionally substituted amino acid; or an optionally substituted di-tri- or tetra-peptide;
- R4 is: hydrogen; alkyl; alkylcarbonyl; (poly)alkoxyalkylene; or dialkoxyphosphoryloxy;
- X is: $\frac{\text{lower alkylene}; N(R')}{\text{---}; S(O)}$; -S(O); -S(O)2—; or X taken together with R^2 is -P(O)(OR');
- Y is: -N(R'); -S; -S(O); $-S(O)_2$; or Y taken together with R^3 is $-P(O)(OR')_2$;
- or X— R^2 taken together with Y— R^3 form an optionally substituted aliphatic or aromatic ring;

U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009

- R' is: hydrogen; alkenyl; optionally substituted alkyl; optionally substituted cycloalkyl; phosphoryl; or optionally substituted aryl;
- R" is: hydrogen; alkenyl; optionally substituted alkyl; or optionally substituted aryl;
- or R' and R" together with the atom to which they are attached form a 5- to 7-membered aromatic, saturated or unsaturated ring, optionally incorporating one or more additional heteroatoms chosen from N, O, or S, and optionally substituted with one or more substituents selected from the group consisting of optionally substituted lower alkyl, halo, cyano, alkylthio, lower alkoxy, carboxy, benzyl, and oxo;
- R" is: hydrogen; alkenyl; optionally substituted alkyl; acyl, optionally substituted cycloalkyl; phosphoryl; or optionally substituted aryl;

or a compound of Formula III:

wherein:

- R⁵ is: —C(O)OR^a; —C(O)NR^aR^b; —CH₂OR^d; —C(O)R^e; cyano; optionally substituted heterocyclyl; or optionally substituted heteroaryl;
- R⁶ is: hydrogen; —C(O)OR*; —C(O)NR*R^b; —CH₂OR^d; —C(O)R°; cyano; optionally substituted alkyl; optionally substituted heterocyclyl; optionally substituted aryl, or optionally substituted heteroaryl;
- or R5 and R6 with the atom to which they are attached form an optionally substituted ring;
- R⁷is: optionally substituted alkyl; optionally substituted cycloalkyl; optionally substituted aryl; optionally substituted aralkyl; optionally substituted heterocyclyl; optionally substituted heterocyclyl; optionally substituted heterocyclyl; an optionally substituted amino acid; or an optionally substituted dri-, tri- or tetra-peptide; with the proviso that when R⁶ is alkyl, then R⁷ is optionally substituted heterocyclyl, optionally substituted heterocyclyl,
- or R⁵ and R⁷ with the atoms to which they are attached form an optionally substituted heterocyclic ring;

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- R⁸ is: hydrogen; alkyl; alkylcarbonyl; (poly)alkoxyalkylene; or dialkoxyphosphoryloxy; Y' is:

 N(R*) → S → ; S(O) → ; or → S(O)₂ → ;
- R^a is: hydrogen; alkenyl; optionally substituted alkyl; optionally substituted cycloalkyl; or optionally substituted aryl;
- R^b is: hydrogen; alkenyl; optionally substituted alkyl; or optionally substituted aryl;
- or R^a and R^b together with the atom to which they are attached form a 5- to 7-membered aromatic, saturated or unsaturated ring, optionally incorporating one or more additional heteroatom chosen from N, O, or S, and optionally substituted with one or more substituents selected from the group consisting of optionally substituted lower alkyl, halo, cyano, alkylthio, lower alkoxy, carboxy, benzyl, and oxo;
- Rc is: optionally substituted alkyl or optionally substituted aryl; and
- R^d is: hydrogen; alkenyl; optionally substituted alkyl; acyl; optionally substituted cycloalkyl; or optionally substituted aryl; including single tautomers, single stereoisomers and mixtures of tautomers and/or stereoisomers, and the pharmaceutically acceptable salts thereof.
- (Original): The method of claim 1, wherein X and Y are both —S—.
- 3. (Currently Amended): A method of treatment for a mammal suffering from a dermatologic condition selected from the group consisting of regulating kin condition, regulating the signs of skin aging or for treating contact dermatitis, skin irritation, acne, rosacea, psoriasis, age-related damage or damage resulting from harmful (UV) radiation or environmental pollution, stress and fatigue comprising administering a therapeutically effective amount of a The method of elaim 1 wherein the compound is selected from:
- R-3-[2-(4-Amino-4-carboxy-butyrylamino)-2-(carboxymethyl-carbamoyl)-ethylsulfanyl]-2-[2-(4-amino-4-carboxy-butyrylamino)-2-(carboxymethyl-carbamoyl-) ethylsulfanylmethyl]-4hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester,
- 3-(5-Chloro-benzothiazol-2-ylsulfanyl)-2-(5-chloro-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Cyclohexylsulfanyl-2-cyclohexylsulfanylmethyl-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- $\label{lem:carbothioylsulfanyl} 4-Hydroxy-5-oxo-3-(pyrrolidine-1-carbothioylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester,$
- 3-(Benzoselenazol-2-ylsulfanyl)-2-(benzoselenazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2.5-dihydro-furan-2-carboxylic acid ethyl ester:
- 4-Hydroxy-5-oxo-3-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-2-(7-trifluoromethyl-quinolin-4-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- 4-Hydroxy-5-oxo-3-(2-sulfo-ethylsulfanyl)-2-(2-sulfo-ethylsulfanylmethyl)-2,5-dihydrofuran-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(4-trifluoromethyl-pyrimidin-2-ylsulfanyl)-2-(4-trifluoromethyl-pyrimidin-2-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(1-oxy-pyridin-2-ylsulfanyl)-2-(1-oxy-pyridin-2-ylsulfanylmethyl)-2.5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-Chloro-phenylsulfanyl)-2-(2-chloro-phenylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Hexyl sulfanyl-2-hexyl sulfanyl methyl-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(1-phenyl-1*H*-tetrazol-5-ylsulfanyl)-2-(1-phenyl-1*H*-tetrazol-5-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(naphthalen-2-ylsulfanyl)-2-(naphthalen-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(4-phenyl-thiazol-2-ylsulfanyl)-2-(4-phenyl-thiazol-2-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-(5-sulfo-1*H*-benzoimidazol-2-ylsulfanyl)-5-(5-sulfo-1*H*-benzoimidazol-2-ylsulfanylmethyl)-3-hydroxy-5-hydroxymethyl-5*H*-furan-2-one;
- 3-(Furan-2-ylmethylsulfanyl)-2-(furan-2-ylmethylsulfanylmethyl)-4-isobutyryloxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-[4-(2-methoxycarbonyl-vinyl)-phenylsulfanyl]-2-[4-(2-methoxycarbonyl-vinyl)-phenylsulfanylmethyl]-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- $\label{lem:condition} 4-Hydroxy-3-(6-nitro-benzothiazol-2-ylsulfanyl)-2-(6-nitro-benzothiazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;$
- 2-(Benzothiazole-2-sulfinylmethyl)-3-(benzothiazol-2-ylsulfanyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2,4-Dichloro-benzylsulfanyl)-2-(2,4-dichloro-benzylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(5-methoxy-benzothiazol-2-ylsulfanyl)-2-(5-methoxy-benzothiazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- 3-(2-Chloro-6-fluoro-benzylsulfanyl)-2-(2-chloro-6-fluoro-benzylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- Dimethylamino-acetic acid 3-(1*H*-benzoimidazol-2-ylsulfanyl)-2-(1*H*-benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-ylmethyl ester;
- 3-(2-Chloro-4-fluoro-phenylsulfanyl)-2-(2-chloro-4-fluoro-phenylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid;
- 2-(Furan-2-ylmethanesulfinylmethyl)-3-(furan-2-ylmethanesulfonyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(furan-2-ylmethanesulfinyl)-2-(furan-2-ylmethanesulfinylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-(2,2-dimethyl-propionyloxy)-3-ethoxycarbonylmethylsulfanyl-2-ethoxycarbonylmethylsulfanylmethyl-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-Dimethylamino-ethylsulfanyl)-2-(2-dimethylamino-ethylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid;
- 3-(5,6-Dichloro-1*H*-benzoimidazol-2-ylsulfanyl)-2-(5,6-dichloro-1*H*-benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Benzyl sulfanyl-2-benzyl sulfanylmethyl-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- $\label{lem:condition} 4-(1H\text{-Benzoimidazol-2-ylsulfanyl})-3-\text{hydroxy-1-oxa-7,9-diaza-spiro}[4,5] \\ \text{dec-3-ene-2,6,8,10-tetraone;}$
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid isopropyl ester;
- $\label{lem:condition} 4-Acetoxy-3-(furan-2-ylmethylsulfanyl)-2-(furan-2-ylmethylsulfanylmethyl)-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;$
- 4-Ethoxy-3-(1-ethyl-1*H*-benzoimidazol-2-ylsulfanyl)-2-(1-ethyl-1*H*-benzoimi- dazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 2-(1*H*-Benzoimidazol-2-ylsulfanylmethyl)-4-ethoxy-3-(1-ethyl-1*H*-benzoimidazol-2-ylsulfanyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Acetoxy-3-benzylsulfanyl-2-benzylsulfanylmethyl-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- 4-Hydroxy-3-(1-methyl-1*H*-benzoimida- zol-2-ylsulfanyl)-2-(1-methyl-1*H*-benzoimidazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- $3\hbox{-}(1H\hbox{-Benzoimidazol-2-ylsulfanyl})\hbox{-}4\hbox{-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;}$
- 4-Hydroxy-3-(5-methyl-1*H*-benzoimidazol-2-ylsulfanyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid 2-isopropyl-5-methyl-cyclohexyl ester;
 - Di-[2-(4-Hydroxy-5-oxo-2-carboxylic acid methyl ester)]-disulfide; and
- $3\hbox{-}(4\hbox{-Fluoro-benzylsulfanyl})\hbox{-} 4\hbox{-hydroxy-} 5\hbox{-}oxo\hbox{-} 5H\hbox{-furan-} 2, 2\hbox{-dicarboxylic acid diethyl ester.}$
- 4. (Currently Amended): A method of treatment for a mammal suffering from a dermatologic condition selected from the group consisting of regulating skin condition, regulating the signs of skin aging or for treating contact dermatitis, skin irritation, acne, rosacea, psoriasis, age-related damage or damage resulting from harmful (UV) radiation or environmental pollution, stress and fatigue comprising administering a therapeutically effective amount of a The method of claim 1 wherein the compound is selected from:
- 3-(5-Chloro-benzothiazol-2-ylsulfanyl)-2-(5-chloro-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Cyclohexylsulfanyl-2-cyclohexylsulfanylmethyl-4-hydroxy-5-oxo-2, 5-dihydro-fur an 2-carboxylic acid ethyl ester;
- 3-(Benzoselenazol-2-ylsulfanyl)-2-(benzoselenazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-fur- an-2-carboxylic acid ethyl ester;
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-Chloro-phenylsulfanyl)-2-(2-chloro-phenylsulfanylmethyl)-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Hexylsulfanyl-2-hexylsulfanylmethyl-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(naphthalen-2-ylsulfanyl)-2-(naphthalen-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(4-phenyl-thiazol-2-ylsulfanyl)-2-(4-pheny- l-thiazol-2-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- 3-(Furan-2-ylmethylsulfanyl)-2-(furan-2-ylmethylsulfanylmethyl)-4-isobutyryloxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2,4-Dichloro-benzylsulfanyl)-2-(2,4-dichloro-benzylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-chloro-4-fluoro-phenylsulfanyl)-2-(2-chloro-4-fluoro-phenylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(furan-2-ylmethanesulfinyl)-2-(furan-2-ylmethanesulfinylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-(2,2-dimethyl-propionyloxy)-3-ethoxycarbonylmethylsulfanyl-2-ethoxycarbonylmethylsulfanylmethyl-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid isopropyl ester;
- $\label{lem:condition} 4-Hydroxy-3-(1-methyl-1\mbox{H-benzoimidazol-2-ylsulfanyl})-2-(1-methyl-1\mbox{H-benzoimidazol-2-ylsulfanylmethyl})-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;$
- $3\hbox{-}(1H\hbox{-Benzoimidazol-2-ylsulfanyl})\hbox{-}4\hbox{-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;}$
- $\label{lem:condition} 4-Hydroxy-3-(5-methyl-1\mbox{H-benzoimidazol-2-ylsulfanyl})-5-oxo-2,5-dihydro-furan-2-carboxylic acid 2-isopropyl-5-methyl-cyclohexyl ester:$
 - Di-[2-(4-Hydroxy-5-oxo-2-carboxylic acid methyl ester)]-disulfide; and
- $\hbox{$3$-(4-Fluoro-benzylsulfanyl)-4-hydroxy-5-oxo-5H-furan-2,2-dicarboxylic acid diethylester.}$
- 5. (Currently Amended): The method of claim [[1]] 3, wherein the condition is selected from regulating skin condition, regulating the signs of skin aging or for treating contact dermatitis, skin irritation, acne, rosacca, and psoriasis, age-related damage or damage resulting from harmful (UV) radiation or environmental pollution, stress or fatigue.
- (Original): The method of claim 1, comprising topically administering at least one compound of Formula I or of Formula III.
- 7. (Original): The method of claim 3, comprising applying to the area of skin in need of such treatment a composition comprising at least one compound selected from:

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- R-3-[2-(4-Amino-4-carboxy-butyrylamino)-2-(carboxymethyl-carbamoyl)-ethylsulfanyl]-2-[2-(4-amino-4-carboxy-butyrylamino)-2-(carboxymethyl-carbamoyl)-ethylsulfanylmethyl]-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(5-Chloro-benzothiazol-2-ylsulfanyl)-2-(5-chloro-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Cyclohexylsulfanyl-2-cyclohexylsulfanylmethyl-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(pyrrolidine-1-carbothioylsulfanyl)-2-(pyrrolidine-1-carbothioylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(Benzoselenazol-2-ylsulfanyl)-2-(benzoselenazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(7-trifluoromethyl-quinolin-4-ylsulfanyl)-2-(7-trifluoromethyl-quinolin-4-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- $\label{lem:condition} 4- Hydroxy-5-oxo-3-(2-sulfo-ethylsulfanyl)-2-(2-sulfo-ethylsulfanylmethyl)-2, 5-dihydrofuran-2-carboxylic acid ethyl ester;$
- 4-Hydroxy-5-oxo-3-(4-trifluoromethyl-pyrimidin-2-ylsulfanyl)-2-(4-trifluoromethyl-pyrimidin-2-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(1-oxy-pyridin-2-ylsulfanyl)-2-(1-oxy-pyridin-2-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-Chloro-phenylsulfanyl)-2-(2-chloro-phenylsulfanylmethyl)-4-hydroxy-5-oxo-2, 5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Hexylsulfanyl-2-hexylsulfanylmethyl-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(1-phenyl-1*H*-tetrazol-5-ylsulfanyl)-2-(1-phenyl-1*H*-tetrazol-5-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(naphthalen-2-ylsulfanyl)-2-(naphthalen-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-5-oxo-3-(4-phenyl-thiazol-2-ylsulfanyl)-2-(4-phenyl-thiazol-2-ylsulfanylmethyl)-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- $\label{eq:condition} 4-(5-sulfo-1H-benzoimidazol-2-ylsulfanyl)-5-(5-sulfo-1H-benzoimidazol-2-ylsulfanylmethyl)-3-hydroxy-5-hydroxymethyl-5H-furan-2-one;$

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- 3-(Furan-2-ylmethylsulfanyl)-2-(furan-2-ylmethylsulfanylmethyl)-4-isobutyryloxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-[4-(2-methoxycarbonyl-vinyl)-phenylsulfanyl]-2-[4-(2-methoxycarbonyl-vinyl)-phenylsulfanylmethyl]-5-oxo-2.5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(6-nitro-benzothiazol-2-ylsulfanyl)-2-(6-nitro-benzothiazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 2-(Benzothiazole-2-sulfinylmethyl)-3-(benzothiazol-2-ylsulfanyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2,4-Dichloro-benzylsulfanyl)-2-(2,4-dichloro-benzylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(5-methoxy-benzothiazol-2-ylsulfanyl)-2-(5-methoxy-benzothiazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-Chloro-6-fluoro-benzylsulfanyl)-2-(2-chloro-6-fluoro-benzylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- Dimethylamino-acetic acid 3-(1*H*-benzoimidazol-2-ylsulfanyl)-2-(1*H*-benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-ylmethyl ester;
- 3-(2-Chloro-4-fluoro-phenylsulfanyl)-2-(2-chloro-4-fluoro-phenylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid;
- 2-(Furan-2-ylmethanesulfinylmethyl)-3-(furan-2-ylmethanesulfonyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(furan-2-ylmethanesulfinyl)-2-(furan-2-ylmethanesulfinylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-(2,2-dimethyl-propionyloxy)-3-ethoxycarbonylmethylsulfanyl-2-ethoxycarbonylmethylsulfanylmethyl-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-(2-Dimethylamino-ethylsulfanyl)-2-(2-dimethylamino-ethylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid;
- 3-(5,6-Dichloro-1*H*-benzoimidazol-2-ylsulfanyl)-2-(5,6-dichloro-1*H*-benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 3-Benzylsulfanyl-2-benzylsulfanylmethyl-4-hydroxy-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;

- U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009
- $\label{lem:condition} 4-(1H\text{-}Benzoimidazol-2-ylsulfanyl)-3-hydroxy-1-oxa-7,9-diaza-spiro[4,5]dec-3-ene-2,6,8,10-tetraone;$
- 3-(Benzothiazol-2-ylsulfanyl)-2-(benzothiazol-2-ylsulfanylmethyl)-4-hydro- xy-5-oxo-2,5-dihydro-furan-2-carboxylic acid isopropyl ester;
- 4-Acctoxy-3-(furan-2-ylmethylsulfanyl)-2-(furan-2-ylmethylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Ethoxy-3-(1-ethyl-1*H*-benzoimidazol-2-ylsulfanyl)-2-(1-ethyl-1*H*-benzoimidazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 2-(1*H*-Benzoimidazol-2-ylsulfanylmethyl)-4-ethoxy-3-(1-ethyl-1*H*-ben-zoimidazol-2-ylsulfanyl)-5-oxo-2,5-dihydro-furan-2-earboxylic acid ethyl ester;
- 4-Acetoxy-3-benzylsulfanyl-2-benzylsulfanylmethyl-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- 4-Hydroxy-3-(1-methyl-1*H*-benzoimidazol-2-ylsulfanyl)-2-(1-methyl-1*H*-benzoimidazol-2-ylsulfanylmethyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid ethyl ester;
- $3\hbox{-}(1H\hbox{-}Benzoimidazol\hbox{-}2\hbox{-}ylsulfanyl)\hbox{-}4\hbox{-}hydroxy\hbox{-}5\hbox{-}oxo\hbox{-}2,5\hbox{-}dihydro\hbox{-}furan\hbox{-}2\hbox{-}carboxylic acid ethyl ester;}$
- 4-Hydroxy-3-(5-methyl-1*H*-benzoimidazol-2-ylsulfanyl)-5-oxo-2,5-dihydro-furan-2-carboxylic acid 2-isopropyl-5-methyl-cyclohexyl ester;
 - Di-[2-(4-Hydroxy-5-oxo-2-carboxylic acid methyl ester)]-disulfide; and
- $\hbox{$3$-(4-Fluoro-benzylsulfanyl)-4-hydroxy-5-oxo-5H-furan-2,2-dicarboxylic acid diethylester.}$
- 8. (Currently Amended): [[7.]] The method of claim 1, comprising administering a formulation for topical application comprising one or more topical excipients and at least one compound of Formula I or of Formula III.
- 9. (Currently Amended): [[8.]] The method of claim 1, additionally comprising an additional benefit agent, selected from sunscreens, retinoid and derivatives thereof, antioxidants, hydroxyacids, botanical extracts, salicylic acid, benzoyl peroxide, antibiotics, antiandrogens, anti-inflammatory agents, vitamins, tocopherol (α -, β -, γ -, δ -) and esters thereof, corticosteroid and mixtures thereof

U.S. Pat. Appl. Ser. No. 10/630,170 Amendment A dated January 12, 2010 Response to the Office Action of September 22, 2009

- 10. (Currently Amended): [[9.]] The method of claim 3, additionally comprising an additional benefit agent, selected from sunscreens, retinoid and derivatives thereof, antioxidants, hydroxyacids, botanical extracts, salicylic acid, benzoyl peroxide, antibiotics, antiandrogens, anti-inflammatory agents, vitamins, tocopherol (α -, β -, γ -, δ -) and esters thereof, corticosteroid and mixtures thereof.
- 11. (New): The method of claim 3, comprising administering a formulation for topical application comprising one or more topical excipients and at least one compound of Formula I or of Formula III.
- (New): The method of claim 4, wherein the condition is selected from contact dermatitis, acne, rosacea, and psoriasis.
- 13. (New): The method of claim 4, additionally comprising an additional benefit agent, selected from sunscreens, retinoid and derivatives thereof, antioxidants, hydroxyacids, botanical extracts, salicylic acid, benzoyl peroxide, antibiotics, antiandrogens, anti-inflammatory agents, vitamins, tocopherol (α -, β -, γ -, δ -) and esters thereof, corticosteroid and mixtures thereof
- 14. (New): The method of claim 4, comprising administering a formulation for topical application comprising one or more topical excipients and at least one compound of Formula II.